Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Of The Week: Express Scripts/Walgreens, Par/TPG, Amicus/GSK

Executive Summary

Following the clinical trial failure of cancer candidate saridegib, Infinity takes back partnered assets from Purdue and plans to go it alone in the PI3K space.

You may also be interested in...



Infinity Regains Pipeline Rights, Gives Up Equity In Rejiggered Purdue Alliance

Infinity avoids the erosion of its rights to a promising PI3K drug by restructuring its alliance with Purdue and Mundipharma, essentially returning all control back to the cancer drug developer.

Par Acquisition By TPG Allows Competing Marriage Proposals

Par will be acquired by private equity firm TPG in $1.9 billion deal if no other suitors come forward with a better offer over the next month.

Weeks After Bydureon Launch, Amylin Looks Like A Takeout Target

The diabetes drug maker has reportedly spurned a buyout offer at a 43% premium, driving up its share price – and perhaps discouraging it from pursuing the partnership it seeks.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel